Sengenics Corporation Announces Fredrik Sundberg as New Vice President of Market and Business Development

BOSTON--(BUSINESS WIRE)--Sengenics Corporation LLC, driving the discovery of next-gen biomarkers through its immunoproteomics platform, announce today that Fredrik Sundberg has joined as the new Vice President of Market and Business Development. With more than 2 decades of experience building strategic customer relationships, Mr. Sundberg promises to help Sengenics identify opportunities for development in the fields of immunology, immuno-oncology, neurological disease, and precision medicine.

“We are delighted to welcome Fredrik to the team. His proven track record of building partnerships and collaborations will help lead us into the next phase of growth,” said Jerry Williamson, President, and CEO of Sengenics. “His unique blend of commercial and scientific expertise will be an important asset in further developing our market.”

Mr. Sundberg has several publications on drug discovery, biosimilars, and validation strategies. He is also a member of the EMEA Pharmaceutical Industry Expert Panel and often lectures on regulatory issues. Mr. Sundberg has held strategic roles of increasing responsibility at Biacore prior to its acquisition by GE Life Sciences, and at GE Life Sciences prior to its acquisition by Danaher, which designated it a standalone business unit now known as Cytiva. Most recently, Mr. Sundberg was Global Director of Strategic Customer Relations at Cytiva.

“I am delighted to have the opportunity to join the Sengenics team,” said Mr. Sundberg. “The company’s unique technology solutions can address several critical challenges across the life sciences research, drug discovery, and development segments. I am looking forward to working with the team to continue developing the market and improving key applications in the precision medicine space. We have an exciting journey ahead!”

About Sengenics

Sengenics is an immunoproteomics company working to improve patient outcomes through physiologically relevant, data-guided decision making. Our solutions enable the discovery and validation of autoantibody biomarker signatures for patient stratification, endotyping and therapeutic response prediction. Sengenics Corporation LLC is headquartered in Greater Boston, Massachusetts, USA and has offices worldwide. Sengenics has more than 50 employees across its current locations. www.sengenics.com